Infiniplex
Fast-lane Cancer Monitoring and Screening
Company Overview
Snapshot
Founded in August 2021 by Zeev Russak and Ofer Peleg, Infiniplex operates with 11–50 employees. The company has raised $1.1 million across one funding round from Terra Venture Partners. In May 2022, Infiniplex secured seed funding from Terra Venture Partners.
Business overview
Infiniplex is a Health Tech & Life Sciences company focused on developing accessible and affordable cancer screening and monitoring solutions. The company's core technology leverages routine blood testing to identify genetic tumor biomarkers, aiming to integrate tumor genomic testing into standard checkups. Infiniplex serves the healthcare industry by providing preemptive, preventive, and follow-up cancer screenings, operating within the Test Diagnostics & Screening sector.
Strategic signal
In May 2022, Infiniplex secured seed funding from Terra Venture Partners. This investment signals early investor confidence in Infiniplex's innovative approach to cancer diagnostics, particularly its focus on utilizing routine blood tests for genetic tumor biomarker screening. For investors and innovation teams, this indicates potential for disruption in the oncology and diagnostics markets, emphasizing the company's forward trajectory in making cancer screening more accessible and affordable.
Company Intelligence Q&A
- When was Infiniplex founded?
- Infiniplex was founded in August 2021.
- Who are the founders of Infiniplex?
- Infiniplex was founded by Zeev Russak and Ofer Peleg.
- What is Infiniplex's primary focus?
- Infiniplex's mission is to utilize routine blood testing to screen for genetic tumor biomarkers and to offer preemptive, preventive, and follow-up cancer screenings at an accessible and affordable cost.
- What was a key funding event for Infiniplex?
- In May 2022, Infiniplex secured $1.1 million in seed funding from Terra Venture Partners.
- What is the product stage of Infiniplex's offerings?
- Infiniplex's products are currently in the R&D stage, with a focus on developing solutions for cancer screening and monitoring.